Issue 2, 23 October 2006 Dear Shareholders Welcome to the second edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments. If you would like any further information, please contact us. Regards John Priest - CEO

HOT TOPIC:

Diabetes behind bulging hospital budgets: new report Diabetes can lead to other serious illnesses and is contributing to skyrocketing health system costs, according to a recent study. The Australian Institute of Health and Welfare report, published in August, reveals over a third of hospitalisations related to diabetes could be prevented with better non-hospital care, such as consistent insulin treatment. This confirms the major market opportunity Apollo Life Sciences has previously identified for its possible world-first insulin in a tablet.

ALSO IN THIS ISSUE:

Apollo proteins used in AIDS prevention quest A leading HIV expert is using a protein custom-made by Apollo Life Sciences in research that could help prevent the spread of AIDS. Apollo's needle-free psoriasis treatment more than skin-deep A psoriasis treatment being developed by Apollo Life Sciences has outperformed market-leading drugs in pre-clinical studies, and is proceeding to Phase 2 trials. Apollo moisturiser gets thumbs up Trials of Apollo Life Sciences' anti-ageing moisturiser at Australia's most prestigious skin testing facility have produced compelling results.

Click here to subscribe

www.apollolifescience.com

 
Apollo Life Sciences Limited  ASX: AOP
Level 1, 147 Queen Street Beaconsfield NSW 2015 Australia
 
If you would prefer not to receive future email communications from Apollo Life Sciences, please
click here or reply to this message with the word REMOVE in the subject field.
You will receive one additional email confirming your removal.